BRCA1 and neoplasm: Advanced ovarian cancer patients with BRCA1/2 germline mutation, treated with platinum-based neo adjuvant chemotherapy prior to surgery, may be expected to have less tumor volume at the time of surgical cytoreduction as compared to those patients without a BRCA1/2 germline mutation.